IL2 and neoplasm: et al. developed tumor-targeted lipid-dendrimer-calcium-phosphate nanoparticles (TT-LDCP) loaded with siRNA silencing immune checkpoint ligand PD-L1 gene and Pdna upregulating expression of the immunostimulating cytokine IL-2 [122] (Figure 4).